FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155044719> ?p ?o ?g. }

• W3155044719 endingPage "3322" @default.
• W3155044719 startingPage "3313" @default.
• W3155044719 abstract "Immune checkpoint inhibitors (ICI) have led to a prolongation of progression-free and overall survival in patients with metastatic Merkel cell carcinoma (MCC). However, immune-mediated adverse events due to ICI therapy are common and often lead to treatment discontinuation. The response duration after cessation of ICI treatment is unknown. Hence, this study aimed to investigate the time to relapse after discontinuation of ICI in MCC patients.We analyzed 20 patients with metastatic MCC who have been retrospectively enrolled at eleven skin cancer centers in Germany. These patients have received ICI therapy and showed as best overall response (BOR) at least a stable disease (SD) upon ICI therapy. All patients have discontinued ICI therapy for other reasons than disease progression. Data on treatment duration, tumor response, treatment cessation, response durability, and tumor relapse were recorded.Overall, 12 of 20 patients (60%) with MCC relapsed after discontinuation of ICI. The median response durability was 10.0 months. Complete response (CR) as BOR to ICI-treatment was observed in six patients, partial response (PR) in eleven, and SD in three patients. Disease progression was less frequent in patients with CR (2/6 patients relapsed) as compared to patients with PR (7/11) and SD (3/3), albeit the effect of initial BOR on the response durability was below statistical significance. The median duration of ICI therapy was 10.0 months. Our results did not show a correlation between treatment duration and the risk of relapse after treatment withdrawal. Major reasons for discontinuation of ICI therapy were CR (20%), adverse events (35%), fatigue (20%), or patient decision (25%). Discontinuation of ICI due to adverse events resulted in progressive disease (PD) in 71% of patients regardless of the initial response. A re-induction of ICI was initiated in 8 patients upon tumor progression. We observed a renewed tumor response in 4 of these 8 patients. Notably, all 4 patients showed an initial BOR of at least PR.Our results from this contemporary cohort of patients with metastatic MCC indicate that MCC patients are at higher risk of relapse after discontinuation of ICI as compared to melanoma patients. Notably, the risk of disease progression after discontinuation of ICI treatment is lower in patients with initial CR (33%) as compared to patients with initial PR (66%) or SD (100%). Upon tumor progression, re-induction of ICI is a feasible option. Our data suggest that the BOR to initial ICI therapy might be a potential predictive clinical marker for a successful re-induction." @default.
• W3155044719 created "2021-04-26" @default.
• W3155044719 creator A5004458225 @default.
• W3155044719 creator A5017152441 @default.
• W3155044719 creator A5022434487 @default.
• W3155044719 creator A5024012524 @default.
• W3155044719 creator A5042429271 @default.
• W3155044719 creator A5042724544 @default.
• W3155044719 creator A5046274963 @default.
• W3155044719 creator A5053254953 @default.
• W3155044719 creator A5057381405 @default.
• W3155044719 creator A5067045121 @default.
• W3155044719 creator A5067776208 @default.
• W3155044719 creator A5069485225 @default.
• W3155044719 creator A5075754000 @default.
• W3155044719 creator A5077331259 @default.
• W3155044719 creator A5082375327 @default.
• W3155044719 creator A5083397493 @default.
• W3155044719 creator A5087671839 @default.
• W3155044719 date "2021-04-18" @default.
• W3155044719 modified "2023-10-15" @default.
• W3155044719 title "Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study" @default.
• W3155044719 cites W2107484016 @default.
• W3155044719 cites W2130066229 @default.
• W3155044719 cites W2510686645 @default.
• W3155044719 cites W2549481046 @default.
• W3155044719 cites W2560367415 @default.
• W3155044719 cites W2572174216 @default.
• W3155044719 cites W2592088712 @default.
• W3155044719 cites W2626596086 @default.
• W3155044719 cites W2765847865 @default.
• W3155044719 cites W2773006694 @default.
• W3155044719 cites W2779503684 @default.
• W3155044719 cites W2800000742 @default.
• W3155044719 cites W2886349478 @default.
• W3155044719 cites W2890527521 @default.
• W3155044719 cites W2904477283 @default.
• W3155044719 cites W2912577878 @default.
• W3155044719 cites W2913997048 @default.
• W3155044719 cites W2917300337 @default.
• W3155044719 cites W2919839730 @default.
• W3155044719 cites W2933124473 @default.
• W3155044719 cites W2934084524 @default.
• W3155044719 cites W3028638056 @default.
• W3155044719 cites W3041665519 @default.
• W3155044719 cites W3083348674 @default.
• W3155044719 doi "https://doi.org/10.1007/s00262-021-02925-4" @default.
• W3155044719 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8505278" @default.
• W3155044719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33870464" @default.
• W3155044719 hasPublicationYear "2021" @default.
• W3155044719 type Work @default.
• W3155044719 sameAs 3155044719 @default.
• W3155044719 citedByCount "14" @default.
• W3155044719 countsByYear W31550447192021 @default.
• W3155044719 countsByYear W31550447192022 @default.
• W3155044719 countsByYear W31550447192023 @default.
• W3155044719 crossrefType "journal-article" @default.
• W3155044719 hasAuthorship W3155044719A5004458225 @default.
• W3155044719 hasAuthorship W3155044719A5017152441 @default.
• W3155044719 hasAuthorship W3155044719A5022434487 @default.
• W3155044719 hasAuthorship W3155044719A5024012524 @default.
• W3155044719 hasAuthorship W3155044719A5042429271 @default.
• W3155044719 hasAuthorship W3155044719A5042724544 @default.
• W3155044719 hasAuthorship W3155044719A5046274963 @default.
• W3155044719 hasAuthorship W3155044719A5053254953 @default.
• W3155044719 hasAuthorship W3155044719A5057381405 @default.
• W3155044719 hasAuthorship W3155044719A5067045121 @default.
• W3155044719 hasAuthorship W3155044719A5067776208 @default.
• W3155044719 hasAuthorship W3155044719A5069485225 @default.
• W3155044719 hasAuthorship W3155044719A5075754000 @default.
• W3155044719 hasAuthorship W3155044719A5077331259 @default.
• W3155044719 hasAuthorship W3155044719A5082375327 @default.
• W3155044719 hasAuthorship W3155044719A5083397493 @default.
• W3155044719 hasAuthorship W3155044719A5087671839 @default.
• W3155044719 hasBestOaLocation W31550447191 @default.
• W3155044719 hasConcept C126322002 @default.
• W3155044719 hasConcept C141071460 @default.
• W3155044719 hasConcept C143998085 @default.
• W3155044719 hasConcept C197934379 @default.
• W3155044719 hasConcept C2777546739 @default.
• W3155044719 hasConcept C2778342957 @default.
• W3155044719 hasConcept C2778715236 @default.
• W3155044719 hasConcept C2778822529 @default.
• W3155044719 hasConcept C2779134260 @default.
• W3155044719 hasConcept C71924100 @default.
• W3155044719 hasConcept C90924648 @default.
• W3155044719 hasConceptScore W3155044719C126322002 @default.
• W3155044719 hasConceptScore W3155044719C141071460 @default.
• W3155044719 hasConceptScore W3155044719C143998085 @default.
• W3155044719 hasConceptScore W3155044719C197934379 @default.
• W3155044719 hasConceptScore W3155044719C2777546739 @default.
• W3155044719 hasConceptScore W3155044719C2778342957 @default.
• W3155044719 hasConceptScore W3155044719C2778715236 @default.
• W3155044719 hasConceptScore W3155044719C2778822529 @default.
• W3155044719 hasConceptScore W3155044719C2779134260 @default.
• W3155044719 hasConceptScore W3155044719C71924100 @default.
• W3155044719 hasConceptScore W3155044719C90924648 @default.
• W3155044719 hasIssue "11" @default.

• next